Palatin Technologies, Inc.
(NYSE Amex Equities : PTN)

( )
PTN PreMarket: $ () as of AM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Pharmaceuticals Major
symbolcompany%chnglast%shortavg$volume
JNJJohnson & Johnson -0.43%178.000.7%$1154.07m
LLYEli Lilly & Co. -0.92%367.001.1%$1126.70m
MRKMerck & Co., Inc. -0.71%109.050.7%$1025.89m
PFEPfizer Inc. -1.02%50.620.9%$981.72m
ABBVAbbVie, Inc. -0.67%160.501.9%$860.26m
BMYBristol-Myers Squibb Co. -0.98%80.081.1%$764.15m
AZNAstraZeneca Plc -0.57%67.951.0%$356.07m
HZNPHorizon Therapeutics Plc 2.10%103.005.4%$315.71m
IDXXIDEXX Laboratories, Inc. -1.92%430.743.9%$225.57m
CTLTCatalent, Inc. 1.46%53.001.9%$216.78m
GSKGSK Plc 0.07%35.060.3%$189.88m
NVSNovartis AG -1.34%88.610.2%$183.84m
NVONovo Nordisk A/S -0.74%125.190.1%$171.53m
ALNYAlnylam Pharmaceuticals, Inc. 0.00%220.258.0%$161.43m
RGENRepligen Corp. 0.00%188.176.7%$134.32m

Company Profile

Palatin Technologies, Inc. is a biopharmaceutical company, which engages in the development of medicines based on molecules that modulate the activity of the melanocortin receptor system. Its primary product candidate is marketed under the Vyleesi brand, the trade name for bremelanotide, which is used for the treatment of premenopausal women with acquired, generalized, hypoactive sexual desire disorder (HSDD). The company was founded by Carl Spana and John K. A. Prendergast on November 21, 1986 and is headquartered in Cranbury, NJ.